Suggested remit - To appraise the clinical and cost effectiveness of nivolumab with ipilimumab within its marketing authorisation for untreated recurrent or metastatic squamous cell cancer of the head and neck
 
Status In progress
Process STA 2018
ID number 1429

Provisional Schedule

Expected publication 22 June 2022

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
13 May 2021 Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
19 February 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer. Please note that following on from information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-August 2021 when we will write to you about how you can get involved.
26 May 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer. Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course.
24 January 2020 In progress. Topic is in progress
07 June 2019 - 05 July 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance